Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2013 | 8 | 5 | 553-557
Tytuł artykułu

The effect of orlistat on body weight in obese Czech adults

Treść / Zawartość
Warianty tytułu
Języki publikacji

Opis fizyczny
  • Department of Military Hygiene, Faculty of Military Health Sciences, University of Defence, Trebesska, Czech Republic,
  • Department of Military Hygiene, Faculty of Military Health Sciences, University of Defence, Trebesska, Czech Republic
  • Language Training Centre, Faculty of Military Health Sciences, University of Defence, Trebesska, Czech Republic
  • [1] Reaven P., Metabolic syndrome, J. Insur. Med., 2004, 36, 132–142
  • [2] Ginter E, Simko V., Adult obesity at the beginning od the 21st century: epidemiology, pathophysiology and health risk, Bratisl. Lek. Listy, 2008, 109, 224–230
  • [3] Waden T.A, Berkowitz R.I, Womble L.G., Randomized trial of lifestyle modification and pharmacotherapy for obesity, N. Engl. J. Med., 2005, 353, 2111–2116[Crossref]
  • [4] Svendsen M, Tonstad S., Orlistat after initial dietary/behavioural treatment: changes in body weight and dietary maintenance in subjects with sleep related breathing disorders, Nutr. J., 2011, 8, 10–21 [WoS]
  • [5] Torp-Pedersen C, Caterson I, Coutinho W., Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial, Eur. Heart. J., 2007, 28(23), 2915–2923[WoS][Crossref]
  • [6] James W.P, Caterson I.D, Coutinho W., Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects, N. Engl. J. Med., 2010, 363(10), 905–917[WoS][Crossref]
  • [7] Hainer V., Comparative efficiency and safety of pharmacological approaches to the management of obesity. Diabetes Care, 2011, 34, 349–354[Crossref][WoS]
  • [8] Bray G.A., Medical therapy for obesity, Mt. Sinai J. Med., 2010, 77(5), 407–417[Crossref]
  • [9] Li Z, Maglione M, Tu W., Pharmacologic treatment of obesity, Ann. Intern. Med., 2005, 142, 532–538[Crossref]
  • [10] Hainer V., Orlistat a perspektivy farmakoterapie obezity, JAMA, 1999, 7, 371–373
  • [11] Li M.F, Cheung B.M., Rise and fall of anti-obesity drugs, World J. Diabetes, 2011, 15(2), 19–23[Crossref]
  • [12] Jain S.S, Ramajane S.J, Akat P.B., Evaluation of efficacy and safety of orlistat in obese patients, Indian J. Endocrinol. Metab., 2011, 15(2), 99–104[Crossref]
  • [13] Derosa G, Maffioli P, Salvadeo S.A., Comparison of orlistat treatment and placebo in obese type 2 diabetic patients, Expert Opin. Pharmacother., 2010, 11(12), 1971–1982[Crossref][WoS]
  • [14] Minarčíková I., Farmakoekonomické aspekty ve farmakoterapii obezity, Česká a Slov. Farm., 2003, 52, 258–261
  • [15] Hainer V., Comment to the article: Assessment of morbid obesity treatment cost efficiency in the Czech Republic, Diab. Metab. Endokr., 2012, 15(3), 199–200
  • [16] Russell-Jones D., Gough S. Recent advances in incretin-based therapies, Clin. Endocrinol. 2012, 77(4), 489–499[WoS][Crossref]
  • [17] Hayes M.R., De Jonghe B.C., Kanoski S.E., Role of the glucagon-like-peptide-1 receptor in the control of energy balance, Physiology and Behavior, 2010, 100(5), 503–510[Crossref]
  • [18] Allison D.B., Gadde K.M., Garvey W.T., Controlledrelease phentermine/topiramate in severely obese adults: a randomized controlled trial, Obesity, 2012, 20(2), 330–42[WoS][Crossref]
  • [19] Gadde K.M., Day W.W., Low-dose, controlledrelease phentermin/topiramate for reduction of weight, Obesity reviews from 11th International Congress on Obesity, 11–15 July 2010 Stockholm, 2010, 11(1), 42–43
  • [20] Ornellas T., Chavez B., A New Approach to Weight Loss in Obese Adults, Pharmacy and Therapeutics, 2011, 36(5), 255–256, 261–262
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.